Interactions between verapamil and digoxin in langendorff-perfused rat hearts: The role of inhibition of P-glycoprotein in the heart

Basic and Clinical Pharmacology and Toxicology

Volumn 107, Issue 5, 2010, Pages 847-852

  Aylin Arici, Mualla ^a   Kilinc, Emrah ^b   Demir, Omer ^a   Ates, Mehmet ^a   Yesilyurt, Alaattin ^b   Gelal, Ayse ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b EGE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; GLYCOPROTEIN P; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG DETERMINATION; DRUG INHIBITION; FEMALE; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CELL; HEART PERFUSION; HEART RATE; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIGOXIN; DRUG INTERACTIONS; FEMALE; HEART RATE; HEART VENTRICLES; P-GLYCOPROTEIN; PERFUSION; RATS; RATS, WISTAR; VENTRICULAR FUNCTION, LEFT; VERAPAMIL;

RATTUS;

EID: 77956065740     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00574.x     Document Type: Article

References (25)

1. Matheny CJ, Lamb MW, Brouwer KR, Pollack GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001;21:778-96.
2. DuBuske LM. The role of P-glycoprotein and organic anion transporting polypeptides in drug interactions. Drug Saf 2005;28:789-801.
3. Lin LH, Yamazaki M. Role of P-Glycoprotein in Pharmacokinetics. Clinical implications. Clin Pharmacokinet 2003;42:59-98.
4. Balayssac D, Authier N, Cayre A, Coudore F.. Does inhibition of P-glycoprotein lead to drug-drug interactions?. Toxicol Lett 2005;156:319-29.
5. Couture L, Nash JA, Turgeon J. The ATP-Binding Cassette Transporters and their implication in drug disposition: a special look at the heart. Pharmacol Rev 2006;58:244-58.
6. Kang W, Weiss M. Influence of P-glycoprotein modulators on cardiac uptake, metabolism, and effects of idarubicin. Pharm Res 2001;18:1535-41.
7. Dec GW. Digoxin remains useful in the management of chronic heart failure. Med Clin North Am 2003;87:317-37.
8. De Lannoy IA, Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 1992;189:551-7.
9. Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA et al. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 2009;85:173-81.
10. Su SF, Huang JD. Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab Dispos 1996;24:142-7.
11. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999;99:552-7.
12. Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 2004;76:73-84.
13. Verschraagen M, Koks CH, Schellens JH, Beijnen JH. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res 1999;40:301-6.
14. Kaplanski J, Weinhouse E, Topaz M, Genchik G. Verapamil and digoxin: interactions in the rat. Res Commun Chem Pathol Pharmacol 1983;42:377-88.
15. Weinhouse E, Kaplanski J, Genchik G. Plasma and tissue levels of digoxin in the rat following pretreatment with verapamil. Res Commun Chem Pathol Pharmacol 1985;47:469-72.
16. Jedlicka A, Grafnetterova T, Miller V. HPLC method with UV detection for evaluation of digoxin tablet dissolution in acidic medium after solid-phase extraction. J Pharm Biochem Anal 2003;33:109-115.
17. Solbach TF, König J, Fromm MF, Zolk O. ATP-binding cassette transporters in the heart. Trends Cardiovasc Med 2006;16:7-15.
18. Eberl S, Renner B, Neubert A, Reisig M, Bachmakov I, König J et al. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet 2007;46:1039-49.
19. Kang W, Weiss M. Digoxin uptake, receptor heterogeneity, and inotropic response in the isolated rat heart: a comprehensive kinetic model. J Pharmacol Exp Ther 2002;302:577-83.
20. Sudergat H, Unger KK, Emmert J, Wendt J, Mandel F. Determination of Digoxin in human serum by LC/MS with online sample preparation, Application Note 2001;15: 5988-4364EN.
21. Schinkel AH, Wagenaar E, Van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96:1698-705.
22. Kawahara M, Sakata A, Miyashita T, Tamai I, Tsuji A. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J Pharm Sci 1999;88:1281-7.
23. Oswald S, Grube M, Siegmund W, Kroemer HK. Transporter-mediated uptake into cellular compartments. Xenobiotica 2007;37:1171-95.
24. Sagawa T, Sagawa K, Kelly JE, Tsushima RG, Wasserstrom JA. Activation of cardiac ryanodine receptors by cardiac glycosides. Am J Physiol Heart Circ Physiol 2002;282:H1118-6.
25. Demiryurek AT, Demiryurek S. Cardiotoxicity of digitalis glycosides: roles of autonomic pathways, autacoids and ion channels. Auton Autacoid Pharmacol 2005;25:35-52.